Cyclic Beta Defensin Analogs for Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides, such as defensins, face challenges including hemolytic activity, salt sensitivity, rapid degradation in human fluids, and complex and costly production processes, limiting their clinical use against infectious diseases, especially for pathogens like Pseudomonas where effective treatments are lacking.
Innovation Solution
Development of cyclic β defensin analogs that maintain the C-terminal tail of hBD3 and specific segments of hBD1-hBD3, with improved synthesis ease, stability, and pharmacokinetics, which can be lipidated or PEGylated for enhanced in vivo profile, and used in pharmaceutical compositions for treating infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear defensins are used to treat infections, then antibacterial activity is achieved, but hemolytic activity and salt sensitivity occur
Solution Approach 1:
The patent divides the linear defensin sequence into modular segments (N-terminal region, C-terminal tail, and internal residues) that can be independently optimized. By segmenting the structure and creating cyclic variants with specific disulfide bond patterns, the invention achieves reduced hemolytic activity and salt sensitivity while preserving antibacterial function.
Solution Approach 2:
The patent systematically varies key parameters including cyclic vs linear configuration, disulfide bond positioning (Cys2-Cys19, Cys6-Cys14, Cys11-Cys9 patterns), and amino acid substitutions to optimize the balance between antibacterial activity and reduced harmful effects like hemolysis and salt sensitivity.
2Reliability
If full-length defensins are synthesized to maintain biological activity, then antimicrobial efficacy is improved, but production complexity and cost increase
Solution Approach 1:
The patent extracts and removes non-essential or problematic regions from the full-length defensin sequence, retaining only the critical functional segments (C-terminal tail and core antimicrobial region). This extraction approach simplifies synthesis while preserving the essential antimicrobial activity.
Solution Approach 2:
The patent employs cyclic peptide structures with stabilized disulfide bonds that are more resistant to proteolytic degradation, effectively creating longer-lasting therapeutic molecules that require lower doses and less frequent administration, thereby reducing overall treatment cost despite initial synthesis complexity.
3Ease of manufacture
If linear defensin structures are used, then synthesis is simpler, but proteolytic degradation occurs rapidly in human fluids
Solution Approach 1:
The patent introduces cyclic constraints through disulfide bonds that segment and stabilize the peptide structure, protecting it from proteolytic enzymes in human fluids while maintaining synthesis feasibility through established cyclic peptide methodologies.
Solution Approach 2:
The patent creates composite structural features by combining cyclic peptide backbones with specific disulfide bond patterns, integrating structural stability with functional activity to achieve resistance against proteolytic degradation while preserving ease of synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic β defensin analogs demonstrate enhanced antibacterial and antiviral activity, particularly against Pseudomonas and other pathogens, with improved stability and reduced salt sensitivity, making them effective therapeutic candidates with potential for large-scale production and effective treatment of various viral and bacterial infections.
Implementation Method 1
Defensins are AMPs showing a characteristic amphipathic nature derived from positive charges and hydrophobic amino acid residues which are organized to assume a three dimensional amphiphatic structure. Defensins are able to disrupt the membrane structure of microorganisms
Implementation Method 2
Six cysteine residues responsible for three intramolecular disulfide bonds combined in different pattern are recognized features of these peptides. The folding of defensins is mainly stabilized by the presence of these three disulphide bonds
Data Source
Figure 1
Figure 2
AI summary
The present invention refers to cyclic β defensins analogs, to their use in the treatment of infections and pharmaceutical compositions containing them.